IBRX Form 144: Proposed 25,000-Share Sale
ImmunityBio, Inc. notice: a Form 144 discloses a proposed sale of 25,000 common shares on 02/23/2026 related to an exercise of stock options.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
ImmunityBio, Inc. notice: a Form 144 discloses a proposed sale of 25,000 common shares on 02/23/2026 related to an exercise of stock options. The filing records prior 10b5-1 sales by Christobel Selecky of 25,000 shares on 01/20/2026 for $187,650 and 50,000 shares on 01/16/2026 for $250,000.
Insights
Routine Form 144 sale notice and recent 10b5-1 transactions; compliance filing records proposed sale and prior executed sales.
The filing lists a proposed sale of 25,000 common shares via exercise of stock options on 02/23/2026. It also itemizes two prior 10b5-1 plan sales by Christobel Selecky: 25,000 shares on 01/20/2026 for $187,650, and 50,000 shares on 01/16/2026 for $250,000.
These entries are administrative notices required under the rules for reporting proposed sales and recent plan activity. Timing, pricing mechanics, and ultimate execution depend on plan terms and broker actions; the filing itself is a disclosure of intent and recent activity rather than a pricing or proceeds statement beyond the listed amounts.
AI-generated analysis. How Rhea-AI works. Not financial advice.